Serum calcitonin gene-related peptide levels in untreated prostate cancer patients

International Journal of Urology

Volumn 13, Issue 6, 2006, Pages 781-784

  Suzuki, Kazumi ^a   Kobayashi, Yutaka ^a   Morita, Tatsuo ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Calcitonin gene related peptide; Prostate cancer; Serum level

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LIVER FUNCTION; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; CALCITONIN GENE-RELATED PEPTIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 33745286282     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01402.x     Document Type: Article

References (25)

1. Weinstein MH Partin AW Veltri RW Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996 27 : 683 7.
2. Yu DS Hsieh DS Chen HI Chang SY. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications. J. Urol. 2001 166 : 871 5.
3. Hirano D Okada Y Minei S Takimoto Y Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur. Urol. 2004 45 : 586 92.
4. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992 70 : 254 68.
5. Berruti A Dogliotti L Mosca A et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann. Oncol. 2001 12 ( Suppl. 2 S153 7.
6. Isshiki S Akakura K Komiya A Suzuki H Kamiya N Ito H. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J. Urol. 2002 167 : 512 15.
7. Berruti A Dogliotti L Mosca A et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000 88 : 2590 7.
8. Kamiya N Akakura K Suzuki H et al. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur. Urol. 2003 44 : 309 14.
9. Lilleby W Paus E Skovlund E Fossa SD. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate 2001 46 : 126 33.
10. Yashi M Muraishi O Kobayashi Y Tokue A Nanjo H. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients. Prostate 2002 51 : 84 97.
11. Yashi M Nukui A Kurokawa S et al. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate 2003 56 : 305 12.
12. Brain SD Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev. 2004 84 : 903 34.
13. Abrahamsson PA Dizeyi N Alm P di Sant'Agnese PA Deftos LJ Aumuller G. Calcitonin and calcitonin gene-related peptide in the human prostate gland. Prostate 2000 44 : 181 6.
14. Crowe R Chapple CR Burnstock G. The human prostate gland: a histochemical and immunohistochemical study of neuropeptides, serotonin, dopamine beta-hydroxylase and acetylcholinesterase in autonomic nerves and ganglia. Br. J. Urol. 1991 68 : 53 61.
15. Gkonos PJ Lokeshwar BL Balkan W Roos BA. Neuroendocrine peptides stimulate adenyl cyclase in normal and malignant prostate cells. Regul. Pept. 1995 59 : 43 51.
16. Nagakawa O Ogasawara M Fujii H et al. Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells. Cancer Lett. 1998 133 : 27 33.
17. Nagakawa O Ogasawara M Murata J Fuse H Saiki I. Effect of prostatic neuropeptides on migration of prostate cancer cell lines. Int. J. Urol. 2001 8 : 65 70.
18. Kubota Y Sasagawa I Sinzawa H et al. Serum levels of free and total prostate-specific antigen in males with liver cirrhosis. Eur. Urol. 1999 36 : 409 12.
19. Sasagawa I Kubota Y Hayami S et al. Serum levels of total and free prostate specific antigen in men on hemodialysis. J. Urol. 1998 160 : 83 5.
20. O'Connor DT Pandlan MR Carlton E Cervenka JH Hslao RJ. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin. Chem. 1989 35 : 1631 7.
21. Strauss GI Christiansen M Moller K Clemmesen JO Larsen FS Knudsen GM. S-100b and neuron-specific enolase in patients with fulminant hepatic failure. Liver Transpl. 2001 7 : 964 70.
22. Strauss GI Edvinsson L Larsen FS Moller K Knudsen GM. Circulating levels of neuropeptides (CGRP, VIP, NPY) in patients with fulminant hepatic failure. Neuropeptides 2001 35 : 174 80.
23. Sassine AM Schulman C. Clinical use of prostate-specific antigen in the staging of patients with prostate carcinoma. Eur. Urol. 1993 23 : 348 51.
24. Ishizuka O Tanabe T Nakayama T Kawakami M Kinebuchi Y Nishizawa O. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan. Int. J. Urol. 2005 12 : 728 32.
25. Spetz AC Pettersson B Varenhorst E Theodorsson E Thorell LH Hammar M. Momentary increase in plasma calcitonin gene-related peptide is involved in hot flashes in men treated with castration for carcinoma of the prostate. J. Urol. 2001 166 : 1720 3.